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There has been increased recognition in recent years of the problems older people face on 4 
discharge from hospital, including those related to medication (1).  In 2011 post-discharge 5 
Medicines Use Reviews (dMURs) were introduced into the English national community pharmacy 6 
contract with the aim of improving medicine support to recently discharged patients who had 7 
experienced changes to their medicines in hospital (2). 8 
However, early reports showed minimal uptake of dMURs, even after signposting by hospitals (3).  9 
Furthermore, there is little evidence of their impact on patient outcomes, with only one recent study 10 
indicating that patients receiving a follow-up consultation with the community pharmacist may have 11 
lower rates of readmission and shorter hospital stays if readmission did occur (4).  The authors 12 
stated that a randomised controlled trial (RCT) of the referral service would be required to fully 13 
investigate the impact on patients but recommended that prior to this, a feasibility study should be 14 
conducted to determine how best to design the trial and identify outcomes that would be feasible to 15 
collect and allow assessment of effectiveness.  16 
Prior to the publication of that research, we had already designed a randomised controlled feasibility 17 
study to evaluate a referral process from hospital to community pharmacy, and have published data 18 
relating to patient recruitment, community pharmacist perceptions of delivering the service, and the 19 
potential clinical and economic impact of interventions made (5-7).  This paper reports on potential 20 
patient outcome measures, used during the feasibility study, that could be utilised in future 21 
evaluations.  22 
Aim 23 
Identify potential outcome measures to investigate the impact of a hospital to community pharmacy 24 
referral service for older patients that utilises the dMUR.  25 
2 
Ethics Approval 26 
Ethics approval for this study was obtained from the Northwest Research Ethics Committee (Ref 27 
13/NW/0779). 28 
Method 29 
Recruitment ran from April 2014 to January 2015. During this period all pharmacists working on 30 
medical wards at Southport and Ormskirk Hospitals NHS Trust (SONT), England, identified in-patients 31 
aged over 65 years who, in their professional opinion, could benefit from a dMUR.  Inclusion and 32 
exclusion criteria have previously been reported (5).  It was intended to recruit between 60 and 100 33 
patients to the feasibility study, in keeping with the usual sample size for pilot and feasibility trials 34 
registered in the UK Clinical Research Network Database.  Baseline demographic data were collected 35 
and compared between participant groups using the chi-squared test for categorical data and an 36 
unpaired t-test for continuous data (Table 1).  37 
Informed consent was obtained from all individual participants included in the study.  Participants 38 
were randomised to receive either a dMUR or standard discharge care.  For those to receive a dMUR, 39 
a referral form and discharge prescription was faxed to their nominated community pharmacist to 40 
allow completion within 28 days as per the national service specification.  41 
All participants were followed up at four weeks and six months post-discharge by the lead researcher 42 
(HR).  At each follow-up point, any hospital admissions or accident and emergency (A&E) visits since 43 
discharge were identified via the hospital’s electronic patient administration system.  If a re-admission 44 
had occurred, a consultant geriatrician and HR reviewed the patient’s notes to evaluate contributing 45 
medication problems.  Published criteria on evaluating medication related hospital admissions 46 
(amended Hallas criteria for causality and Hepler criteria for preventability) were used during these 47 
sessions (8). 48 
All participants were sent a postal questionnaire at each follow-up.  Questionnaires combined 49 
questions relating to self-management of medicines and medication reviews participated in since 50 
discharge, with scales measuring medication adherence and health-related quality of life (HR-QoL).  51 
3 
Medication adherence was measured using the validated 8-item Morisky Medication Adherence Scale 52 
(MMAS) and HR-QoL, using the 12-Item Short-Form Health Survey, version 2 (SF-12v2) (9,10).  53 
Additionally, a measurement of patient enablement following dMUR was derived for the intervention 54 
group participants at the 4 week follow-up, using the Patient Enablement Index (PEI) (11). 55 
Data on readmissions, A&E visits, adherence and HR-QoL for each participant were collated in an 56 
Excel spreadsheet.  It was acknowledged that the small number of participants to be recruited 57 
during this feasibility study meant that it would be underpowered to detect statistically significant 58 
differences in quantitative outcomes between groups.  However, for methodological rigour, and in 59 
preparation for any future RCT, various statistical tests were applied: 60 
• The proportion of participants in each group having one or more readmission during the follow-61 
up period (dichotomous data) was compared using Chi-squared at both 4-week and 6-month 62 
follow-up.   63 
• The total number of readmissions in each group (ordered discrete data) was compared at both64 
follow-up points using the Mann-Whitney U-test. 65 
• The mean length of readmission episodes in each group was compared using the Mann-66 
Whitney U Test. 67 
• The proportion of participants in each group having one or more A&E visit (but being discharged68 
from here rather than admitted to a hospital ward) was compared using Chi-squared at both 69 
follow-up points. 70 
• The total number of A&E visits in each group was compared at both follow-up points using the71 
Mann-Whitney U-test.  72 
• SF12-v2 and MMAS scores were treated as continuous numerical data and compared between73 
groups using an unpaired t-test at both follow-up points. 74 
• Previous studies have reported the mean PEI with a 95% CI.  Therefore the same practice was75 
employed here for intervention group participants who received a dMUR and returned a 76 




A total of 59 participants (30 intervention and 29 control) were recruited to the study.  There were no 80 
significant differences in baseline characteristics between study groups (Table 1).  However, the 81 
intervention group tended towards being more likely to live alone, and to have had a previous 82 
admission within the last 30 days (not significant due to small participant numbers). 83 
Insert new Table 1 here 84 
All participants were followed up with respect to readmissions and A&E visits at both time points. 85 
Fifteen participants (6 intervention and 9 control) did not return the 4-week questionnaire and 23 86 
participants (9 intervention and 14 control) did not return the 6-month questionnaire.  In just under 87 
half of cases the reasons for this are known, and included death (n=2), participant admitted to a 88 
care home (n=3), participant no longer responsible for managing their own medication (n=4), and 89 
participant in hospital at time of final follow-up (n=2).  The number of usable questionnaires returned 90 
represents a 61% return rate.  Results of an intention to treat analysis including all randomised 91 
participants showed no significant differences in any of the quantitative outcomes studied between 92 
intervention and control groups at either four-week or six-month follow-up  (Tables 1 and 2).  93 
Insert new table 2 here 94 
The mean PEI for intervention group participants who received a dMUR and returned a scorable 95 
questionnaire (n=16) was 3.69 (95% confidence interval (CI) 1.68-5.70). 96 
Overall, 19% of the total study population (control and intervention) were readmitted at least once 97 
within 4 weeks of their original discharge, rising to 53% by 6 months, representing 49 readmissions. 98 
Case-notes for 48 readmissions were located and analysed.  Twelve (25%) of these were possibly, 99 
probably or definitely medication related according to the amended Hallas criteria (8).  Seven 100 
(58.3%) of the medication related readmissions were classed as at least possibly preventable using 101 
the Hepler criteria (8).  There were no preventable medication related readmissions involving 102 





This study is the first to investigate ways of measuring the effect on patient outcomes of hospital 107 
referrals to community pharmacies for dMUR in older patients.  Importantly for a feasibility study, we 108 
have demonstrated that recruitment of older patients to a randomised study of this nature is 109 
possible.  The fact that 41% (n=24) of participants completed this study as per protocol is in 110 
keeping with research conducted by others indicating that studies involving older patients 111 
experience high attrition rates (12).  Death, or deterioration in health leading to participants being 112 
readmitted, moving address to live in locations where their care needs can be better met, or simply 113 
being no longer able to complete follow-up measures all contribute to this and were all observed 114 
during this study.  115 
In addition, difficulties with the delivery of the dMUR intervention to housebound patients by 116 
community pharmacists in this study meant that only fourteen intervention group participants (47%) 117 
received their dMUR as per study protocol and a further 6 received it after the 4-week time-point. 118 
The format of the current nationally commissioned service appears to hinder accessibility to this 119 
patient group, specifically via the facilitation of domiciliary visits, as discussed in our previous 120 
publications (5-7). 121 
 Taking this factor into consideration, the outcome measures selected and the use of postal 122 
questionnaire to collect data from participants appear appropriate to take forward to a future scaled 123 
up evaluation. 124 
The lack of significant differences in outcomes between control and intervention groups reported is 125 
not unexpected, as the study was not designed or powered to detect such differences.  However, 126 
findings do indicate trends worthy of further investigation; in particular, the trend towards shorter 127 
length of stay on readmission for the intervention group, which was also seen in Nazar et al’s 128 
evaluation (4).   In the present study, one in seven readmissions occurring within the 6-month 129 
6 
follow-up period were judged as both medicines related and preventable, which is consistent with 130 
previous reports and indicates that the criteria used were successful in identifying such 131 
readmissions.  The finding that no preventable medication related readmissions occurred among 132 
patients who completed a dMUR suggests that they could be effective in preventing such 133 
readmissions.  Therefore, preventable medication related readmissions is an appropriate outcome 134 
measure for any future large study. 135 
The MMAS scores in both study groups indicated overall medium to high adherence at both follow-136 
up points, which may reflect over-reporting of adherence by participants or recruitment bias, 137 
whereby adherent patients were more likely to agree to participant in the study.    In a future larger 138 
study it is recommended that, in addition to actual MMAS score, the proportion of patients falling 139 
into the categories of low versus medium or high adherence should be analysed between groups.  140 
This would allow comparison of results with those of the English community pharmacy New 141 
Medicines Service evaluation, which also used the MMAS (13).  Consideration should also be given 142 
to using a second measure of adherence, such as pharmacy refill records, to provide an internal 143 
check on validity. 144 
In this study, mean physical HR-QoL score at six months was 5.39 points higher in the intervention 145 
group than the control.  Scale up of this study is needed to see if these findings can be reproduced 146 
and represent real change in physical health-related quality of life following dMUR referral. 147 
The mean enablement score following dMUR in this study, although similar to the scores of patients 148 
aged > 65 in Howie et al’s original study of GP consultations, fell short of the score (> 6) deemed 149 
necessary for clinically meaningful enablement (11).  This could be due in part to the high levels of 150 
adherence reported by participants, leaving little capacity for improvement or enablement. 151 
This work is limited by the small-scale nature of the study, involving one hospital and the associated 152 
community pharmacists.  This means that the findings cannot be generalised to other settings.  153 
However this was not the purpose of the study, which was designed to assess the feasibility of the 154 
7 
dMUR referral service and the chosen outcome measures in preparation for a future RCT, the 155 
results of which would be generalisable. 156 
Additionally, difficulties with delivery of the dMUR in the intervention group mean that confounding is 157 
possible in that patients who were well enough to attend the pharmacy for a dMUR may have been 158 
intrinsically less likely to be readmitted to hospital.  It is not known whether a dMUR would have 159 
prevented readmissions among intervention group participants who were unable to attend their 160 
dMUR, had they completed the intervention as planned.  161 
Conclusion 162 
Recruitment and follow-up of older patients in a randomised study of referral from hospital to 163 
community pharmacy, using the protocol described, is feasible.  The outcome measures used to 164 
analyse readmissions, medicines adherence, HR-QoL and patient enablement appear appropriate 165 
for evaluation of the service.  166 
This feasibility study should be scaled up to a full pilot study, followed by an adequately powered 167 
RCT, in order to further investigate the effect on patient outcomes of dMUR referral. 168 
169 
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Table 1: Participant Baseline Characteristics 214 
 215 








for I vs C 
Test 
used 
Female (%) 33 (56) 16 (53) 17 (59) 0.6826 Chi-
squared 
Mean Age in years (Range) 78 (65-92) 79 (68-92) 77 (6-89) 0.1142 T-test
Living alone (%) 19 (32) 13 (43) 6 (21) 0.0628 Chi-
squared 
Mean number meds 
(Range) 
9 (2-19) 9 (3-16) 9 (2-19) NA NA 
Mean MCI (Range) 20 (5 - 41.5) 21 (7.5–41.5) 19 (5-40.5) 0.3476 T-Test




4 (2-8) 4 (2-8) 4 (2-8) NA NA 
Admission in last 30 days 
(%) 
11 (19) 8 (27) 3 (10) 0.108 Chi-
squared 
Admission in last 12 
months (%) 
29 (47) 15 (53) 13 (45) 0.6908 Chi-
squared 
Mean length baseline 
admission in days (Range) 






Table 2: Participant Outcomes  219 






for I vs C 
Test 
used 
Patients having > 1 non-elective readmission 6 (20%) 5 (17.2%) 0.7377 Chi-
squared 
Total number of non-elective readmissions 8 6 0.8026 Mann- 
Whitney 
Mean Length of Readmissions (days) 4.38 7.00 0.1713 Mann- 
Whitney 
Patients having > 1 A&E attendance 7 (23.3%) 8(27.6%) 0.7643 Chi-
squared 
Total number of A&E attendances 9 9 1 NA 
Outcomes Assessed Via Questionnaire n=24 n=20   
Morisky Medication Adherence Score (MMAS)  7.20 7.54 0.3475 T-test 
Health related Quality of Life (SF-12v2) Physical 34.77 34.50 0.9174 T-test 
Health related Quality of Life (SF-12v2) Mental 44.41 42.68 0.6164 T-test 






for I vs C 
Test 
used 
Patients having > 1 non-elective readmission 15 (50%) 16 (55.2%) 0.7924 Chi-
squared 
Total number of non-elective readmissions 26 23 0.9690 Mann- 
Whitney 
Mean Length of Readmissions (days) 5.67 7.04 0.4487 T-test 
Time to First Readmission (days) 72.87 57.81 0.4315 T-test 
Patients having > 1 A&E attendance 16 (53.3%) 17 (58.6%) 0.7909 Chi-
squared 
Total number of A&E attendances 36 32 0.9690 T-test 
Outcomes Assessed Via Questionnaire n=21 n=15   
Morisky Medication Adherence Score (MMAS) 7.40 7.22 0.5916 T-test 
Health related Quality of Life (SF-12v2) Physical 40.80 35.41 0.0983 T-test 
Health related Quality of Life (SF-12v2) Mental 43.42 45.34 0.5384 T-test 
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